LatticeFlow AI Sets a New Standard for AI Governance With Evidence-Based Technical Assessments
LatticeFlow AI, the Swiss deep-tech company advancing trustworthy and compliant AI, today announced the Early Access Program for AI GO!, the first platform that enables AI Governance Operations through deep technical assessments. With this, LatticeFlow AI sets a new standard for AI governance and compliance, enabling organizations to accelerate their AI advantage.
Traditional Governance, Risk and Compliance (GRC) systems, based on checklists, are insufficient to govern complex and rapidly evolving AI systems. LatticeFlow AI GO! provides rigorous, evidence-based assessments that uncover AI risks, generate audit-ready insights, and empower confident decision-making. The platform equips AI risk and compliance teams with the visibility and confidence they need to harness the full potential of GenAI applications, chatbots, and the latest LLMs.
“The only way AI governance can work and scale is when it’s grounded in technical evidence,” said Petar Tsankov, CEO and Co-Founder of LatticeFlow AI. “With AI GO!, enterprises gain the deep insights they need to manage AI risks, prove compliance, and accelerate innovation with confidence.”
Building on its leadership as co-creator of COMPL-AI (the first framework to assess GenAI models against the EU AI Act) and grounded in Swiss precision and scientific rigor, LatticeFlow AI sets a new standard for doing AI governance right. The company transforms complex AI systems into transparent, auditable, and trustworthy insights enterprises can rely on for any framework, standard or regulation, such as NIST, ISO, and the EU AI Act.
More information and demos of LatticeFlow AI GO! are available on this link.
Getting AI Governance Right Through Evidence and Trust
With AI GO!, LatticeFlow AI enables organizations to get AI governance right by combining rigorous technical assessments with the automation required to apply consistent oversight across departments and use cases.
Given its AI-first governance approach, the new platform allows teams to leverage out-of-the box AI risk frameworks, such as the EU AI Act, or add their own, custom AI risk frameworks, ensuring AI governance aligns with business needs.
In addition, LatticeFlow AI GO! is extensible across modalities and applications, from GenAI, LLMs, chatbots, to Computer Vision and Tabular models, providing a unified way to evaluate performance, safety, and compliance for any AI system.
Finally, the new platform supports a wide range of critical use cases, validating GenAI applications and chatbots, screening LLMs, assessing third-party AI risks, and ensuring compliance with regulations, such as the EU AI Act.
Advancing Evidence-Based EU AI Act Compliance
Building on its role as co-creator of COMPL-AI, the first framework to map EU AI Act principles to concrete technical controls, LatticeFlow AI is at the forefront of advancing evidence-based compliance. Most recently, the company delivered the first EU AI Act compliance-centered analysis of the Swiss LLM Apertus, which became the first large AI model compliant with the EU AI Act, further demonstrating its ability to translate regulatory principles into transparent, auditable technical assessments enterprises can rely on.
“The EU AI Act is a turning point for the industry,” added Dr. Tsankov. “It demands concrete technical evidence that AI systems are safe and trustworthy. With AI GO!, we help enterprises meet compliance head-on while continuing to drive innovation and value.”
Broad Industry Support
LatticeFlow AI’s industry leadership was recently highlighted at Trustworthy AI in Practice, a flagship event co-hosted with ETH Zurich last September 9th. The event underscored LatticeFlow AI’s deep scientific roots and its unique ability to convey the full AI ecosystem.
The event was a resounding success, uniting thought leaders from academia, industry, big tech, and enterprises to advance the discussion on making trustworthy AI a reality.
A key takeaway from the event was the pressing need for AI governance operations. Adrian Ott, Chief AI Officer at EY Switzerland, highlighted: “For successful AI transformation in businesses, it's crucial that AI innovation and risk management work in tandem rather than operating in opposition.”
Dr. Matthias Bossardt, Partner and Head of Cyber & Digital Risk at KPMG Switzerland, added: “To benefit from AI at scale, organizations must establish robust AI governance processes that enable efficient risk and performance monitoring.”
From the research and innovation view, Dr. Imanol Schlag, Technical Lead of the recently launched Swiss LLM Apertus, stressed: “The Swiss AI Initiative proves that large-scale efforts don't have to choose between capability and transparency.”
Finally, from a technology perspective, Dr. Naya Giannakopoulou, Senior Technical Architect at Microsoft Innovation Hub, remarked: “The future of enterprise-scale AI lies in guardrails that turn governance into an accelerator, not a blocker.”
Together, these perspectives reflect a shared vision: advancing AI governance through deep technical assessments that deliver trust, compliance, and innovation at scale.
About LatticeFlow AI
LatticeFlow AI sets a new standard in AI governance with deep technical assessments that enable evidence-based decisions and empower enterprises to accelerate their AI advantage.
As the creator of COMPL-AI, the world’s first EU AI Act framework for Generative AI developed with ETH Zurich and INSAIT, the company combines Swiss precision with scientific rigor to scale AI governance built on evidence and trust.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250917686559/en/
Contacts
Gloria Fernandez, Marketing Director, LatticeFlow AI - media@latticeflow.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 15:30:00 EEST | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 15:00:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD ® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 15:00:00 EEST | Press release
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in Barcelona. “As the only high-efficacy short-course oral treatment, MAVENCLAD has demonstrated sustained benefits across a variety of outcomes—extending beyond relapses and MRI—without requiring continuous immunosuppression,” said Alex Kulla, Senior Vice President & Global Head of the Neurology & Immunology Medical Unit for the Healthcare business of Merck. “With over two decades of clinical experience an
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 15:00:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1b/2a study with lead drug candidate RLS-1496 in patients with actinic keratosis. RLS-1496 is a first-in-class disease-modifying selective glutathione peroxidase 4 (GPX4) modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process. The study is expected to begin in Q4 2025. The first EMA-cleared RLS-1496 clinical trial began in May 2025 for plaque psoriasis, atopic dermatitis, and skin aging (photoaged skin); study results are expected in Q4 2025. Actinic keratosis is a rough, scaly patch caused by sun exposure that appears on sun-exposed areas of the skin, such as
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 15:00:00 EEST | Press release
Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers to higher-acuity care units, achieved through earlier detection and intervention to prevent patient deterioration.2-5 Now, in this new retrospective analysis – involving 3-1/2 years of data and almost
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom